| Autor: |
Blanch-Rubió J; Rheumatology Service, Hospital del Mar, Passeig Marítim, Barcelona 08003 , Spain.; IMIM (Hospital del Mar Medical Research Institute), PRBB, Barcelona 08003, Spain., Soldevila-Domenech N; Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, PRBB, Barcelona 08003, Spain.; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, PRBB, Barcelona 08003, Spain., Tío L; IMIM (Hospital del Mar Medical Research Institute), PRBB, Barcelona 08003, Spain., Llorente-Onaindia J; IMIM (Hospital del Mar Medical Research Institute), PRBB, Barcelona 08003, Spain., Ciria-Recasens M; Rheumatology Service, Hospital del Mar, Passeig Marítim, Barcelona 08003 , Spain.; IMIM (Hospital del Mar Medical Research Institute), PRBB, Barcelona 08003, Spain., Polino L; IMIM (Hospital del Mar Medical Research Institute), PRBB, Barcelona 08003, Spain., Gurt A; CAP Vila Olímpica, Parc Sanitari Pere Virgili, Barcelona 08005, Spain., de la Torre R; Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, PRBB, Barcelona 08003, Spain.; Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, PRBB, Barcelona 08003, Spain., Maldonado R; IMIM (Hospital del Mar Medical Research Institute), PRBB, Barcelona 08003, Spain.; Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, PRBB, Barcelona 08003, Spain., Monfort J; Rheumatology Service, Hospital del Mar, Passeig Marítim, Barcelona 08003 , Spain.; IMIM (Hospital del Mar Medical Research Institute), PRBB, Barcelona 08003, Spain. |
| Abstrakt: |
Coronavirus disease 19 (COVID-19) is currently a global pandemic that affects patients with other pathologies. Here, we investigated the influence of treatments for osteoporosis and other non-inflammatory rheumatic conditions, such as osteoarthritis and fibromyalgia, on COVID-19 incidence. To this end, we conducted a cross-sectional study of 2,102 patients being treated at the Rheumatology Service of Hospital del Mar (Barcelona, Spain). In our cohort, COVID-19 cumulative incidence from March 1 to May 3, 2020 was compared to population estimates for the same city. We used Poisson regression models to determine the adjusted relative risk ratios for COVID-19 associated with different treatments and comorbidities. Denosumab, zoledronate and calcium were negatively associated with COVID-19 incidence. Some analgesics, particularly pregabalin and most of the studied antidepressants, were positively associated with COVID-19 incidence, whereas duloxetine presented a negative association. Oral bisphosphonates, vitamin D, thiazide diuretics, anti-hypertensive drugs and chronic non-steroidal anti-inflammatory drugs had no effect on COVID-19 incidence in the studied population. Our results provide novel evidence to support the maintenance of the main anti-osteoporosis treatments in COVID-19 patients, which may be of particular relevance to elderly patients affected by the SARS-CoV-2 pandemic. |
